Media & News

Latest News

  • LCT granted USA Patent for Auckland Island Pigs
    February 2012
    Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has been granted U.S. Patent No. 8,088,969 from the United States Patent and Trademark Office (USPTO). The patent, which was issued on 3 January 2012 and expires on 10 November 2028, provides exclusive rights to the use of cells and tissue derived from Auckland Island pigs for xenotransplantation therapies. It protects the holder’s ability to commercialise therapies based on its core cell encapsulation and xenotransplantation capabilities.
    Download PDF version
  • LCT appoints chief executive
    December 2011
    Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has appointed Dr Andrea Grant as Chief Executive Officer. Dr Grant joins LCT from Roche Products New Zealand Ltd, where as Public Policy and Communications Manager she was responsible for government and corporate relations.
    Download PDF version
  • LCT AGM Chairman Address November 2011
    November 2011
    Download PDF version
  • LCT AGM CEO Address November 2011
    November 2011
    Download PDF version
  • Settlement of $A50 million JV to commercialise DIABECELL
    November 2011
    LCT is pleased to announce that settlement of the transactions relating to the 50/50 joint venture company Diatranz Otsuka Limited with Otsuka Pharmaceutical Factory, Inc. has been successfully completed.
    Download PDF version
  • LCT Files Appendix 4C Quarterly Cash Flow Report
    October 2011
    LCT announced today the quarterly cash flow report for the quarter ended 30 September 2011. The cash balance at the end of the quarter was $2,875,447 compared to $4,504,677 at 30 June 2011.
    Download PDF version